Cytomegalovirus (HHV-5) Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Cytomegalovirus (HHV-5) Infections – Pipeline Review, H2 2016’, provides an overview of the Cytomegalovirus (HHV-5) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections

The report reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Cytomegalovirus (HHV-5) Infections therapeutics and enlists all their major and minor projects

The report assesses Cytomegalovirus (HHV-5) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adicet Bio, Inc.

AIMM Therapeutics BV

Astellas Pharma Inc

Atara Biotherapeutics Inc

AvidBiotics Corp

Biotest AG

Chimerix Inc

China Biologic Products Inc

CyTuVax BV

Fate Therapeutics Inc

GlaxoSmithKline Plc

Hookipa Biotech AG

Kadmon Corp LLC

Laboratoires Thea SA

Merck & Co Inc

Microbiotix Inc

Mymetics Corp

Novartis AG

Pfizer Inc

Phoenix Biotechnology Inc

Savoy Pharmaceuticals, Inc.

Sigma-Tau SpA

Themis Bioscience GmbH

Trellis Bioscience Inc

Vakzine Projekt Management GmbH

VBI Vaccines Inc

Vical Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Cytomegalovirus (HHV-5) Infections Overview 9

Therapeutics Development 10

Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview 10

Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis 11

Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies 12

Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes 14

Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Cytomegalovirus (HHV-5) Infections - Products under Development by Companies 20

Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes 23

Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 25

Adicet Bio, Inc. 25

AIMM Therapeutics BV 26

Astellas Pharma Inc 27

Atara Biotherapeutics Inc 28

AvidBiotics Corp 29

Biotest AG 30

Chimerix Inc 31

China Biologic Products Inc 32

CyTuVax BV 33

Fate Therapeutics Inc 34

GlaxoSmithKline Plc 35

Hookipa Biotech AG 36

Kadmon Corp LLC 37

Laboratoires Thea SA 38

Merck & Co Inc 39

Microbiotix Inc 40

Mymetics Corp 41

Novartis AG 42

Pfizer Inc 43

Phoenix Biotechnology Inc 44

Savoy Pharmaceuticals, Inc. 45

Sigma-Tau SpA 46

Themis Bioscience GmbH 47

Trellis Bioscience Inc 48

Vakzine Projekt Management GmbH 49

VBI Vaccines Inc 50

Vical Inc 51

Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 52

Assessment by Monotherapy Products 52

Assessment by Combination Products 53

Assessment by Target 54

Assessment by Mechanism of Action 56

Assessment by Route of Administration 58

Assessment by Molecule Type 60

Drug Profiles 62

AIC-387 - Drug Profile 62

AIC-476 - Drug Profile 63

AIC-813 - Drug Profile 64

AL-18 - Drug Profile 65

Antibody for Human Cytomegalovirus Infection - Drug Profile 66

ASP-0113 - Drug Profile 67

brincidofovir - Drug Profile 70

BT-084 - Drug Profile 84

Cellular Immunotherapy for Cytomegalovirus and Adenovirus Infections - Drug Profile 85

Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 86

Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 87

Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 88

Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 89

Cellular Immunotherapy for Cytomegalovirus Infections and GBM - Drug Profile 90

Cellular Immunotherapy for Infectious Disease - Drug Profile 91

Cellular Immunotherapy for Infectious Diseases - Drug Profile 92

Cellular Immunotherapy for Viral Infections - Drug Profile 93

Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile 94

Cellular Immunotherapy to Target CMV Antigen for Cytomegalovirus Infections - Drug Profile 95

Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 96

Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 98

Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile 99

CMX-669 - Drug Profile 100

CSJ-148 - Drug Profile 101

CyMVectin - Drug Profile 102

cytomegalovirus (virus like particle) vaccine - Drug Profile 104

Cytomegalovirus (virus like particle) vaccine - Drug Profile 105

Cytomegalovirus vaccine - Drug Profile 106

Cytomegalovirus vaccine - Drug Profile 107

Cytomegalovirus vaccine - Drug Profile 108

filociclovir - Drug Profile 109

ganciclovir - Drug Profile 111

Gene Therapy for Cytomegalovirus Infections - Drug Profile 112

HB-101 - Drug Profile 113

letermovir - Drug Profile 114

maribavir - Drug Profile 117

MBX-2168 - Drug Profile 120

Monoclonal Antibodies to Inhibit HLA-A2 for Cytomegalovirus Infections - Drug Profile 121

Monoclonal Antibody for Cytomegalovirus Infections - Drug Profile 122

Monoclonal Antibody to Agonize LTbR for CMV Infection - Drug Profile 123

Pentamer - Drug Profile 124

Peptides to Inhibit Heparan Sulfate for HHV-5 Infections - Drug Profile 125

PepVax - Drug Profile 126

ProTmune - Drug Profile 128

PTX-3 - Drug Profile 130

RBT-301 - Drug Profile 131

Recombinant Peptide for Infectious Diseases - Drug Profile 132

Recombinant Protein for CMV - Drug Profile 133

RKP-00156 - Drug Profile 134

Small Molecule for Cytomegalovirus - Drug Profile 135

Small Molecules for CMV Infections - Drug Profile 136

Small Molecules for CMV infections and Cancer - Drug Profile 137

Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile 138

Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile 139

Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases - Drug Profile 140

Small Molecules to Inhibit Na+/K+ ATPase for Human Cytomegalovirus Infections - Drug Profile 141

Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile 142

Triplex - Drug Profile 143

TRL-345 - Drug Profile 145

V-160 - Drug Profile 146

VBI-1501A - Drug Profile 147

Viralym-C - Drug Profile 149

Viroprev - Drug Profile 150

VPM-2001 - Drug Profile 151

Cytomegalovirus (HHV-5) Infections - Dormant Projects 152

Cytomegalovirus (HHV-5) Infections - Discontinued Products 157

Cytomegalovirus (HHV-5) Infections - Product Development Milestones 158

Featured News & Press Releases 158

Appendix 172

Methodology 172

Coverage 172

Secondary Research 172

Primary Research 172

Expert Panel Validation 172

Contact Us 172

Disclaimer 173

List of Tables

List of Tables

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2016 14

Number of Products under Development for Cytomegalovirus (HHV-5) Infections – Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Late Stage Development, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Development, H2 2016 22

Comparative Analysis by Unknown Stage Development, H2 2016 23

Products under Development by Companies, H2 2016 24

Products under Development by Companies, H2 2016 (Contd..1) 25

Products under Development by Companies, H2 2016 (Contd..2) 26

Products under Investigation by Universities/Institutes, H2 2016 27

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 28

Cytomegalovirus (HHV-5) Infections – Pipeline by Adicet Bio, Inc., H2 2016 29

Cytomegalovirus (HHV-5) Infections – Pipeline by AIMM Therapeutics BV, H2 2016 30

Cytomegalovirus (HHV-5) Infections – Pipeline by Astellas Pharma Inc, H2 2016 31

Cytomegalovirus (HHV-5) Infections – Pipeline by Atara Biotherapeutics Inc, H2 2016 32

Cytomegalovirus (HHV-5) Infections – Pipeline by AvidBiotics Corp, H2 2016 33

Cytomegalovirus (HHV-5) Infections – Pipeline by Biotest AG, H2 2016 34

Cytomegalovirus (HHV-5) Infections – Pipeline by Chimerix Inc, H2 2016 35

Cytomegalovirus (HHV-5) Infections – Pipeline by China Biologic Products Inc, H2 2016 36

Cytomegalovirus (HHV-5) Infections – Pipeline by CyTuVax BV, H2 2016 37

Cytomegalovirus (HHV-5) Infections – Pipeline by Fate Therapeutics Inc, H2 2016 38

Cytomegalovirus (HHV-5) Infections – Pipeline by GlaxoSmithKline Plc, H2 2016 39

Cytomegalovirus (HHV-5) Infections – Pipeline by Hookipa Biotech AG, H2 2016 40

Cytomegalovirus (HHV-5) Infections – Pipeline by Kadmon Corp LLC, H2 2016 41

Cytomegalovirus (HHV-5) Infections – Pipeline by Laboratoires Thea SA, H2 2016 42

Cytomegalovirus (HHV-5) Infections – Pipeline by Merck & Co Inc, H2 2016 43

Cytomegalovirus (HHV-5) Infections – Pipeline by Microbiotix Inc, H2 2016 44

Cytomegalovirus (HHV-5) Infections – Pipeline by Mymetics Corp, H2 2016 45

Cytomegalovirus (HHV-5) Infections – Pipeline by Novartis AG, H2 2016 46

Cytomegalovirus (HHV-5) Infections – Pipeline by Pfizer Inc, H2 2016 47

Cytomegalovirus (HHV-5) Infections – Pipeline by Phoenix Biotechnology Inc, H2 2016 48

Cytomegalovirus (HHV-5) Infections – Pipeline by Savoy Pharmaceuticals, Inc., H2 2016 49

Cytomegalovirus (HHV-5) Infections – Pipeline by Sigma-Tau SpA, H2 2016 50

Cytomegalovirus (HHV-5) Infections – Pipeline by Themis Bioscience GmbH, H2 2016 51

Cytomegalovirus (HHV-5) Infections – Pipeline by Trellis Bioscience Inc, H2 2016 52

Cytomegalovirus (HHV-5) Infections – Pipeline by Vakzine Projekt Management GmbH, H2 2016 53

Cytomegalovirus (HHV-5) Infections – Pipeline by VBI Vaccines Inc, H2 2016 54

Cytomegalovirus (HHV-5) Infections – Pipeline by Vical Inc, H2 2016 55

Assessment by Monotherapy Products, H2 2016 56

Assessment by Combination Products, H2 2016 57

Number of Products by Stage and Target, H2 2016 59

Number of Products by Stage and Mechanism of Action, H2 2016 61

Number of Products by Stage and Route of Administration, H2 2016 63

Number of Products by Stage and Molecule Type, H2 2016 65

Cytomegalovirus (HHV-5) Infections – Dormant Projects, H2 2016 156

Cytomegalovirus (HHV-5) Infections – Dormant Projects (Contd..1), H2 2016 157

Cytomegalovirus (HHV-5) Infections – Dormant Projects (Contd..2), H2 2016 158

Cytomegalovirus (HHV-5) Infections – Dormant Projects (Contd..3), H2 2016 159

Cytomegalovirus (HHV-5) Infections – Dormant Projects (Contd..4), H2 2016 160

Cytomegalovirus (HHV-5) Infections – Discontinued Products, H2 2016 161

List of Figures

List of Figures

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2016 14

Number of Products under Development for Cytomegalovirus (HHV-5) Infections – Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Comparative Analysis by Late Stage Development, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Products, H2 2016 22

Assessment by Monotherapy Products, H2 2016 56

Number of Products by Top 10 Targets, H2 2016 58

Number of Products by Stage and Top 10 Targets, H2 2016 58

Number of Products by Top 10 Mechanism of Actions, H2 2016 60

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 60

Number of Products by Routes of Administration, H2 2016 62

Number of Products by Stage and Routes of Administration, H2 2016 62

Number of Products by Top 10 Molecule Types, H2 2016 64

Number of Products by Stage and Top 10 Molecule Types, H2 2016 64

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports